A synthetic RIG-I–specific agonist, mimicking the structure of the influenza virus panhandle promoter (CBS-13-BPS), triggered significant tumor regression in a murine pancreatic tumor model (Lee et al., 2018). Here, RIGI is linked to pancreatic neoplasm.